Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients

Cancer

Volumn 115, Issue 8, 2009, Pages 1631-1637

  Walter, Christian ^a,b   Al Nawas, Bilal ^b   Bois, Andreas Du ^c   Buch, Laura ^b   Harter, Philipp ^c   Grötz, Knut A ^b,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Bisphosphonate; Bisphosphonate associated osteonecrosis of the jaws; Bone metastasis; Breast cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; GERMANY; HUMAN; INCIDENCE; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MAXILLA RESECTION; PREVALENCE; PRIORITY JOURNAL; STRUCTURED INTERVIEW; TOOTH EXTRACTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; HUMANS; INCIDENCE; JAW DISEASES; MIDDLE AGED; ORAL SURGICAL PROCEDURES; OSTEONECROSIS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 65249098369     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24119     Document Type: Article

References (50)

1. Pavlakis N, Schmidt R, Stockier M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005: CD003474.
2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165-176.
3. Amin D, Cornell SA, Gustafson SK, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 1992; 33:1657-1663.
4. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. Jun 15. 2000;88(suppl):2961-2978.
5. Diel IJ, Bergner R, Grotz KA. Adverse effects of bisphosphonates: current issues. J Support Oncol. 2007;5:475-482.
6. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg. 2003;61:1115-1117.
7. Walter C, Grotz KA, Kunkel M, Al-Nawas B. Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. Support Care Cancer. 2007;15:197-202.
8. Tarassoff P, Csermak K. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg. 2003;61:1238-1239.
9. Grotz KA, Walter C, Kuttner C, Al-Nawas B. [Relevance of bisphosphonate long-term therapy in radiation therapy of endosteal jaw metastases.]. Strahlenther Onkol. 2007;183:190-194.
10. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620.
11. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005;63:1567-1575.
12. Reszka AA, Halasy-Nagy J, Rodan GA. Nitrogen- bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol. 2001;59:193-202.
13. Grotz KA, Al-Nawas B. Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg. 2006; 64:1571-1572.
14. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. JDent Res. 2007;86:1013-1021.
15. Grotz KA, Kreusch T. Zahnarztliche Betreuung von Patienten unter/nach Bisphosphonat-Medikation. DZZ. 2006;60:10.
16. Walter C, Al-Nawas B, Grotz KA, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol. 2008;54:1066-1072.
17. Grotz KA. Zahnarztliche Betreuung von Patienten mit tumortherapeutischer Kopf-Hals-Bestrahlung. DZZ. 2002;57:509-511.
18. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl JMed. 2005;353:99-102.
19. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23:8580-8587.
20. Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg. 2007;65: 1328-1331.
21. Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Suarez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis. Ann Oncol. 2007;18:556-560.
22. Sanna G, Preda L, Bruschini R, et al. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer. Ann Oncol. 2006;17:1512-1516.
23. Cigler T, Goss PE. Breast cancer adjuvant endocrine therapy. Cancer J. 2007;13:148-155.
24. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol. 2008;19:1407-1416.
25. Kluth EV, Jain PR, Stuchell RN, Frich JC Jr. A study of factors contributing to the development of osteoradionecrosis of the jaws. J Prosthet Dent. 1988;59:194-201.
26. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538-6544.
27. Saarland Ministerium fur Justiz, Gus. 40 Jahre epidemiologisches Krebsregister Saarland 1967-2007 Dokumentieren, Informieren, Evaluieren 2007. Saarland: Ministerium fur Justiz.
28. Montal S, Tramini P, Triay JA, Valcarcel J. Oral hygiene and the need for treatment of the dependent institutionalised elderly. Gerodontology. 2006;23:67-72.
29. Hughes DE, Wright KR, Uy HL, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
30. Green JR, Clezardin P. Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol. 2002;25(suppl 1):S3-S9.
31. Igarashi K, Hirafuji M, Adachi H, Shinoda H, Mitani H. Effects of bisphosphonates on alkaline phosphatase activity, mineralization, and prostaglandin E2 synthesis in the clonal osteoblast-like cell line MC3T3-E1. Prostaglandins Leukot Essent Fatty Acids. 1997;56:121-125.
32. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone. 1998;22:455-461.
33. Abe Y, Kawakami A, Nakashima T, et al. Etidronate inhibits human osteoblast apoptosis by inhibition of pro-apoptotic factor(s) produced by activated T cells. J Lab Clin Med. 2000;136:344-354.
34. Itoh F, Aoyagi S, Furihata-Komatsu H, et al. Clodronate stimulates osteoblast differentiation in ST2 and MC3T3-E1 cells and rat organ cultures. Eur JPharmacol. 2003;477:9-16.
35. Pan B, Farrugia AN, To LB, et al. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE). JBoneMinerRes. 2004; 19:147-154.
36. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials. 2004;25:4105-4115.
37. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374.
38. Guarneri V, Donati S, Nicolini M, Giovannelli S, D'Amico R, Conte PF. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist. 2005;10:842-848.
39. Hoff AO, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res. 2008;23:826-836.
40. Ibrahim T, Barbanti F, Giorgio-Marrano G, et al. Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: a retrospective study. Oncologist. 2008;13:330-336.
41. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol. 2006;24:945-952.
42. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massen- keil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 2008;44:857-869.
43. Calvo-Villas JM, Tapia Torres M, Govantes Rodriguez J, Carreter de Granda E, Sicilia GuillénF.[Osteonecrosisofthe jawin patients with multiple myeloma during and after treatment with zoledronic acid]. Med Clin (Barc). 2006;127:576-579.
44. Corso A, Varettoni M, Zappasodi P, et al. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia. 2007;21:1545-1548.
45. Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica. 2006; 91:968-971.
46. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foa R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica. 2007;92:1289-1290.
47. Tosi P, Zamagni E, Cangini D, et al. Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone. Blood. 2006;108:3951-3952.
48. Zervas K, Verrou E, Teleioudis Z, et al. Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients. Br J Haematol. 2006;134:620-623.
49. Garcia Saenz JA, Lopez Tarruella S, Garcia Paredes B, Rodriguez Lajusticia L, Villalobos L, Diaz Rubio E. Osteonecrosis of the jaw as an adverse bisphosphonate event: 3 cases of bone metastatic prostate cancer patients treated with zoledronic acid. Med Oral Patol Oral Cir Bucal. 2007;12:E351-E356.
50. Ortega C, Montemurro F, Faggiuolo R, et al. Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: a retrospective analysis. Acta Oncol. 2007;46:664-668.